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Abstract: The introduction of pneumococcal conjugate vaccines PCV7 and PCV13 led to decreases in
incidence of pediatric invasive pneumococcal disease (pIPD) and changes in serotype distribution.
We evaluated the consequences of higher vaccine uptake after the introduction of PCV13 in the
National Immunization Plan (NIP) in 2015. Besides culture and conventional serotyping, the use
of molecular methods to detect and serotype pneumococci in both pleural and cerebrospinal fluid
samples contributed to 30% of all pIPD (n = 232) in 2015–2018. The most frequently detected serotypes
were: 3 (n = 59, 26%), 10A (n = 17, 8%), 8 (n = 16, 7%) and 19A (n = 10, 4%). PCV13 serotypes still
accounted for 46% of pIPD cases. Serotypes not included in any currently available conjugate vaccine
(NVT) are becoming important causes of pIPD, with the increases in serotypes 8 and 33F being of
particular concern given the importance of serotype 8 in adult IPD and the antimicrobial resistance
of serotype 33F isolates. This study highlights the importance of using molecular methods in pIPD
surveillance since these allowed a better case ascertainment and the identification of serotype 3 as
the leading cause of pIPD. Even in a situation of vaccine uptake >95% for 3 years, PCV13 serotypes
remain important causes of pIPD.
Keywords: conjugate vaccine; serotype; invasive disease; epidemiology; molecular diagnostics;
antimicrobial resistance
1. Introduction
Pneumococcal conjugate vaccines (PCVs) have already proven to be highly effec-
tive in preventing invasive pneumococcal disease (IPD). Routine infant immunization
led to an overall decrease in the incidence of pediatric IPD (pIPD), but also indirectly
in non-immunized adults through the reduction of carriage and transmission of vaccine
serotypes [1–8]. Additionally, changes in serotype distribution were also detected, with a
decrease in the proportion of IPD cases caused by serotypes included in vaccine formula-
tions, with the notable exception of serotype 3, which has not been decreasing as much in
most countries where PCV13 is being used [8–11].
In Portugal, the introduction of conjugate vaccines began in 2001, when PCV7, tar-
geting serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, became available. Soon after this, the
proportion of pediatric IPD cases caused by serotypes included in the vaccine decreased,
mostly due to declines of serotypes 4, 6B, 14 and 23F [2]. However, similar to many other
countries, these changes were accompanied by a rise in non-PCV7 serotypes 1, 7F and
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19A [1,2]. Higher valency vaccines became available in 2009 (PCV10, targeting PCV7
serotypes and serotypes 1, 5 and 7F) and in 2010 (PCV13, targeting PCV10 serotype and
serotypes 3, 6A and 19A). Even though only available through the private market, PCV7
uptake was high, reaching 75% around 2008 [1] but, after PCV13 introduction, vaccine
uptake decreased to 62% and remained approximately constant until 2014 [12]. Besides the
changes in serotype distribution, it was also possible to detect a decrease in the incidence
of pIPD from 8.19 cases per 100,000 in 2008–2009 to 4.52/100,000 in 2011–2012. In contrast,
from 2012–2013 to 2014–2015, the incidence of pIPD varied only slightly and without a
clear trend, suggesting that no further benefits of vaccination could be expected with the
coverage existing at the time. Moreover, PCV13 serotypes were still responsible for the
majority of pIPD cases (58%), of which serotypes 3, 14 and 1 were the most frequently
detected. The frequent detection of serotype 3, only possible due to the use of molecular
methods, such as real-time PCR, was particularly worrisome because it was associated
with vaccine failures in a considerable number of cases [3,12]. Potential reasons for the
persistence of PCV serotypes could include a high antimicrobial consumption and the
resistance found in some of the PCV serotypes, particularly isolates of serotypes 14, 19A,
19F and 6B [3], a slower vaccine uptake or a lower vaccination coverage when compared
to countries where PCVs are included in the national immunization program (NIP). At
the same time the non-PCV13 serotypes 15B/C, 24F and 10A became important causes of
disease [3], in agreement with what was being reported in other European countries [13].
In July 2015, PCV13 was introduced in the NIP for children born after January 2015,
in a 2 + 1 schedule, with doses given at 2, 4 and 12 months of age, quickly reaching
>95% coverage [14]. Two other higher valency vaccines, a 15-valent (PCV15) and a 20-
valent (PCV20) vaccine are currently obtaining regulatory approval [15,16] potentially
offering additional prevention options for pIPD. The aims of this work were to determine
the serotype distribution and antimicrobial susceptibility profiles of the pneumococcal
population causing pIPD in a period of almost universal vaccination with PCV13.
2. Materials and Methods
The Portuguese Group for the Study of Streptococcal Infections and the Portuguese
Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society
have been monitoring pneumococcal invasive infections in Portugal since 2007. The study
was approved by the Institutional Review Board of the Centro Académico de Medicina
de Lisboa. As these were considered surveillance activities, they were exempt from in-
formed consent. All methods were performed in accordance with the relevant guidelines
and regulations.
The data and isolates were de-identified so that these were irretrievably unlinked to
an identifiable person. Reporting of isolates and patient samples was performed by the
microbiology laboratories and pediatric departments of 55 hospitals throughout Portugal.
All centers reported during the entire period. A case of pIPD was defined as a person
(<18 years) from whom an isolate of S. pneumoniae was recovered from a normally sterile
body site (not including middle ear fluid) or from whom pneumococcal DNA was detected
in cerebrospinal fluid (CSF) or pleural fluid. Only isolates recovered between 1 July 2015
and 30 June 2018 were included in the present study. Epidemiological years were defined as
spanning from 1 July to 30 June of the following year. Only one isolate from each patient in
a 90-day interval was included. Cases ascertained and isolates and samples recovered up to
June 2015 were previously characterized [1–3,17,18]. Strains were identified as S. pneumoniae
by colony morphology and hemolysis on blood agar plates, optochin susceptibility and
bile solubility. In the case where the IPD diagnosis was made by molecular methods, the
detection of pneumococci was performed by molecular methods using two S. pneumoniae
genes (lytA and wzg) used for identification [12].
Serotyping was performed by the standard capsular reaction test using the chessboard
system and specific sera (Statens Serum Institut, Copenhagen, Denmark). Given the high
frequency of spontaneous switching between serotypes 15B and 15C, we decided to group
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isolates with these serotypes into a single group. Additionally, given the difficulties in
phenotypically distinguishing isolates of serotypes 25A and 38, as well as isolates with
serotypes 29 and 35B, these also grouped together into 25A/38 and 29/35B, respectively. In
cases where the diagnosis was performed by molecular methods, the serotypes were also
determined by real-time PCR with a reaction targeting 21 serotypes [12]. Serotypes were
classified into vaccine serotypes (VT), i.e., those included in PCV7 (serotypes 4, 6B, 9V, 14,
18C, 19F, 23F), the additional three found in PCV10 relative to PCV7 (addPCV10: 1, 5, 7F),
the additional three found in PCV13 relative to PCV10 (addPCV13: 3, 6A, 19A), and non-
vaccine serotypes (NVT) indicating serotypes not included in PCV13. The additional two
serotypes included in PCV15 relative to PCV13 (addPCV15: 22F, 33F) and the additional
five serotypes included in PCV20 relative to PCV15 (addPCV20: 8, 10A, 11A, 12F, 15B) were
also discriminated. Since the PCR reaction includes probes for all PCV13 serotypes, when a
serotype could not be identified using this method the case was grouped into the NVT cases.
The only serotype included in PCV20 and not detected by the PCR reaction employed is
serotype 10A but other serotypes could also not be distinguished from other closely related
serotypes [12] and are indicated as such. Etest strips (AB Biodisk, Solna, Sweden) were
used to determine the minimal inhibitory concentrations (MICs) for penicillin, cefotaxime,
ceftriaxone, and levofloxacin. Unless otherwise stated, we used the CLSI-recommended
breakpoints for oral penicillin [19] as epidemiological breakpoints, allowing the comparison
with previous studies.
Isolates were further characterized by determining their susceptibility to erythromycin,
clindamycin, vancomycin, linezolid, tetracycline, trimethoprim–sulfamethoxazole and chlo-
ramphenicol by the Kirby–Bauer disk diffusion technique, according to the CLSI recommen-
dations and interpretative criteria [19]. Macrolide resistance phenotypes were identified
using a double-disc test with erythromycin and clindamycin. Simultaneous resistance
to erythromycin and clindamycin defines the MLSB phenotype (resistance to macrolides,
lincosamides and streptogramin B) while non-susceptibility only to erythromycin indicates
the M phenotype.
The Fisher exact test was used for differences in proportion with the false discovery
rate (FDR) correction for multiple testing [20], and the Cochran–Armitage test was used
for trends. A p < 0.05 was considered significant for all tests.
3. Results
Between July 2015 and June 2018, 223 IPD cases were reported. In 70 cases (31.4%)
diagnosis was only possible using molecular methods directly from patient samples and in
the remaining 153 cases (68.6%) an isolate was sent to our laboratory for characterization.
Most available isolates were recovered from blood (n = 115, 75.5%), with the remaining
being recovered from CSF (n = 24, 15.7%), pleural fluid (n = 8, 5.2%), peritoneal fluid (n = 5,
3.3%) and synovial fluid (n = 1, 0.6%). Among the 70 samples for which only pneumococcal
DNA was available, pleural fluid was the most frequent patient sample (n = 63, 90%)
and the remaining 10% of the positive samples (n = 7) were recovered from the CSF. The
distribution of IPD cases by epidemiological year and age group is summarized in Table 1.
Table 1. Cases of invasive pneumococcal disease from patients <18 years, Portugal, July 2015–June
2018 (n = 223).
Epidemiological
Years 1
Cases by Age Group
0–11 Months 12–23 Months 2–4 Years 5–17 Years Total
2015–2016 16 16 18 17 67
2016–2017 23 6 25 19 73
2017–2018 23 17 27 16 83
Total 62 39 69 52 223
1 From 1 July to 30 June of the following year.
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3.1. Serotype Distribution
Among the 223 isolates and patient samples, 30 different capsular types were detected
(Figure 1). In 15 cases in which pneumococci were directly identified by PCR from a
patient sample, it was not possible to unambiguously determine the serotype. In three
samples, a group of related serotypes could be present in each of the samples—11A/11D
(n = 1), 12A/12B/12F (n = 1) and 15B/C (n = 1). In 12 samples (5.4%) a serotype could
not be identified by PCR but since our PCR reaction identified all serotypes present in
PCV13 these samples were classified as NVT. Additionally, given the high frequency of
spontaneous switching between serotypes 15B (n = 7) and 15C (n = 1) we decided to group
isolates with these serotypes into a single group, 15B/C (n = 9, including the one patient
sample in which the serotype was determined by PCR and no distinction between the two
could be made). Given difficulties in unequivocally distinguish phenotypically isolates of
serotypes 25A and 38, as well as serotype 29 and 35B, these were also grouped together
into 25A/38 (n = 7) and 29/35B (n = 4).
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Figure 1. Number of samples representing serotypes present in conjugate vaccines causing invasive infections in Portugal
(2015–2016 to 2017–2018). The number of samples representing each serotype in each of the age groups considered is
indicated. Isolates presenting both erythromycin resistance and penicillin nonsusceptibility (EPNSP) are represented by red
bars. Penicillin no -susceptible solates (PNS ) are indicated by orange bars. E yth omycin-resistant isolates (ERSP) are
indicated by yellow bars. I olates susceptible to both penicill n and erythromycin are represented by gre n bars. here
pneu ococci ere detected exclusively by P R or here the isolate was lost before antimicrobial susceptibility testing
and for which susceptibility is unknown, are indicated by white bars. The serotypes included in each of the conjugate
vaccines are indicated by the arrows. NVT—non-vaccine serotypes, i.e., serotypes not included in any of the currently
available conjugate vaccines (PCV7, PCV10 and PCV13). The values indicated below the arrows are the proportion of each
group in the overall cases (n = 223). Serotypes 4, 5, 7F, 9V, 18C included in PCV13, PCV10 or PCV7 were not detected in the
study years.
Overall, the most frequent serotypes were serotype 3 (n = 59, 26.5%), followed by
serotype 10A (n = 17, 7.6%), serotype 8 (n = 16, 7.2%) and serotype 19A (n = 10, 4.5%). PCV7
serotypes represented 12.6% of the cases (n = 28) of which only serotypes 14 (n = 9), 19F
(n = 8), 6B (n = 6), 23F (n = 4) and 18C (n = 1) were detected (Figures 1 and 2). Among
the addPCV10 serotypes only serotype 1 was detected (n = 5, 2.2%) and only in the first
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two epidemiological years. Overall, a considerable proportion of IPD cases were still
associated to the addPCV13 serotypes (n = 69, 30.9%). Among the NVTs the addPCV20
serotypes accounted for a large fraction of the isolates (n = 37), mostly due to serotypes 8
and 10A which were among the most frequent overall, while the addPCV15 serotypes were
represented by fewer isolates (n = 16). Two isolates were non-typeable. Among the cases
in which pneumococci were identified in the CSF the following serotypes were found: 8,
15B/C, 19A (n = 3 each); 3, 15A, 34, 22F, 19F (n = 2 each); and 6B, 9N, 10A, 12A/12B/12F,
21, 24, 25A/38, 27, 29/35B (n = 1 each).
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Figure 2. Number of samples representing serotypes not present in previously and currently available conjugate vaccines
causing invasive infections in Portugal (2015–2016 to 2017–2018). See the legend of Figure 1. NT—Non-typeable. Some
serotypes could not be unambiguously determined and are indicated as such (see text). Among the 15B/C IPD cases are
eight in which isolates could be recovered—15B (n = 7) and 15C (n = 1)—and one detected by PCR. The proportion of
isolates expressing serotypes represented in PCV15 and PCV20 is 51% and 61%, respectively. The potential coverage of
PCV20 was calculated excluding the three samples in which the serotyp s could not b unambiguously identified and that
included PCV20 serotypes: 15B/C, 11A/D and 12A/B/F. Since our PCR serotyping schema does not detect serotype 10A
it is possible that some of the samples for which a serotype could not be identified (“Not PCV by PCR”) represent this
serotype which could further increase the potential coverage of PCV20.
Considering the serotypes of the previously and currently available conjugate vaccines,
it was possible to detect significant differences when comparing the period in analysis with
the previously reported period (2012–2015). While the proportion of PCV7 and addPCV10
serotypes decreased from 21.6% to 12.6% (p = 0.010) and from 15.9% to 2.2% (p < 0.001),
respectively, the proportion of cases associated with addPCV13 increased from 20.3% to
30.9% (p = 0.010). An increase was also seen in the proportion of NVT cases, from 42.2%
in 2012–2015 to 54.3% in 2015–2018 (p = 0.011). Moreover, when considering individual
serotypes (n > 10 when considering both periods) in all age groups, we found significant
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differences in the proportion of some serotypes in pIPD, when comparing to the previous
period (2012–2015). Significant increases were seen in the proportion of serotypes: 3 (from
13.8% to 26.5%, p = 0.001), 8 (from 2.2% to 7.2%, p = 0.013) and 33F (from 0.4% to 4%,
p = 0.010), all significant after FDR correction. In contrast, significant decreases were
detected in the proportion of pIPD of the PCV13 serotypes: 1 (from 9.9% to 2.2%, p = 0.007),
14 (from 9.9% to 4.0%, p = 0.017) and 7F (from 6.0% to 0%, p < 0.001), all significant after
FDR correction. Non-significant increases were observed in the PCV serotype 19F (from
2.6% to 3.6%), and NVT serotypes 10A (from 4.3% to 7.6%) and 15A (from 1.3% to 3.1%).
Non-significant decreases in the PCV serotypes 19A (from 5.6% to 4.5%), 23F (from 2.6% to
1.8%) and 6B (from 5.2% to 2.7%), as well as NVT serotypes 15B/C (from 5.2% to 4%) and
24F (from 4.3% to 2.7%), were also observed.
The serotype distribution among the different age groups is summarized in Table 2.
Considering only serotypes with >5 isolates, we found that serotype 3 cases increased with
age (p < 0.001, significant after FDR correction), whereas the NVT serotypes 15B/C and 33F
cases decreased with age (p = 0.020 and p = 0.010, respectively, but neither significant after
FDR correction). Overall, infections in younger children were more frequently associated
with NVT serotypes (71.0% and 74.4% in the age groups 0–11 months and 11–23 months,
respectively) (p < 0.001).
Table 2. Serotype distribution of Streptococcus pneumoniae isolates responsible for invasive disease
in patients < 18 years, Portugal, July 2015–June 2018, among the different age groups (for serotypes
with n > 5).








1 1 (1.6%) 0 (0%) 1 (1.4%) 3 (5.8%) 0.16
3 4 (6.5%) 5 (12.8%) 32 (45.7%) 18 (34.6%) <0.001
8 7 (11.3%) 1 (2.6%) 4 (5.7%) 4 (7.7%) 0.50
14 2 (3.2%) 0 (0%) 4 (5.7%) 3 (5.8%) 0.29
10A 6 (9.7%) 5 (12.8%) 4 (5.7%) 2 (3.8%) 0.15
15A 3 (4.8%) 2 (5.1%) 1 (1.4%) 1 (1.9%) 0.24
15B/C 2 5 (8.1%) 3 (7.7%) 0 (0%) 1 (1.9%) 0.02
19A 4 (6.5%) 0 (0%) 5 (7.1%) 1 (1.9%) 0.57
19F 3 (4.8%) 1 (2.6%) 1 (1.4%) 3 (5.8%) 0.99
22F 3 (4.8%) 0 (0%) 4 (5.7%) 0 (0%) 0.40
25A/38 1 (1.6%) 3 (7.7%) 3 (4.3%) 0 (0%) 0.62
33F 5 (8.1%) 3 (7.7%) 1 (1.4%) 0 (0%) 0.01
6B 2 (3.2%) 3 (7.7%) 1 (1.4%) 0 (0%) 0.14
1 CA: Cochran–Armitage test for trend. In bold are values significant after FDR correction. 2 The actual number
of isolates of each serotype was 15B, n = 7 and 15C, n = 1. In one case the serotype was determined directly from
the patient sample and no distinction between these serotypes was possible.
3.2. Antimicrobial Susceptibility
Antimicrobial susceptibility testing was performed on 151 available isolates (2 isolates
were lost after serotyping) and is summarized in Figures 1 and 2 and in Table 3. Overall,
21 isolates (13.9%) were nonsusceptible to penicillin (PNSP), of which all expressed low-
level resistance. Considering the current CLSI breakpoints for parenteral penicillin, n = 6/24
(25%) CSF isolates would have been considered resistant and, assuming none of the
other isolates would be associated with meningitis cases, none of those would have been
considered non-susceptible. If we also apply the penicillin meningitis breakpoints to
blood isolates, n = 13/114 (11%) would have been considered resistant. A blood isolate
was considered non-susceptible to ceftriaxone and cefotaxime with the non-meningitis
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breakpoints (MICs of 2.0 µg/mL and 1.5 µg/mL, respectively). If using the meningitis
breakpoints this isolate would have been considered resistant to ceftriaxone and cefotaxime
and two additional blood isolates would have been considered non-susceptible. Resistance
to erythromycin was found in 26 isolates (17.2%), of which the majority expressed the
MLSB phenotype (84.6%) and only 15.5% of the isolates expressed the M phenotype.
Table 3. Antimicrobial resistance of Streptococcus pneumoniae isolates responsible for invasive disease
in patients <18 years, Portugal, July 2015–June 2018 (n = 151).
Antibiotic 1









PEN 3 9 (15.5) 3 (9.1) 5 (14.7) 4 (15.4)
MIC90 4 0.125 0.023 0.25 0.5
MIC50 4 0.012 0.012 0.012 0.008
CRO 3 0 (0) 0 (0) 1 (2.9) 0 (0)
MIC90 4 0.047 0.032 0.25 0.38
MIC50 4 0.012 0.012 0.012 0.012
CTX 3 0 (0) 0 (0) 1 (2.9) 0 (0)
MIC90 4 0.047 0.032 0.38 0.38
MIC50 4 0.016 0.016 0.016 0.012
ERY 10 (17.2) 8 (24.2) 5 (14.7) 3 (11.5)
CLI 9 (15.5) 6 (18.2) 4 (11.8) 3 (11.5)
CHL 0 (0) 1 (3.0%) 0 (0) 0 (0)
SXT 5 (8.6) 5 (15.2) 4 (11.8) 2 (7.7)
TET 8 (13.8) 5 (15.2) 4 (11.8) 1 (3.8)
VAN 0 (0) 0 (0) 0 (0) 0 (0)
LVX 0 (0) 0 (0) 0 (0) 0 (0)
LZD 0 (0) 0 (0) 0 (0) 0 (0)
1 CHL: chloramphenicol; CLI: clindamycin; CRO: ceftriaxone; CTX: cefotaxime; ERY: erythromycin; LVX: lev-
ofloxacin; LZD: linezolid; PEN: penicillin; SXT: trimethoprim–sulfamethoxazole; TET: tetracycline; VAN: van-
comycin. 2 Unless otherwise specified. 3 Number and percentage of non-susceptible isolates are indicated.
4 MIC—minimal inhibitory concentration inhibiting the growth of 50% (MIC50) or 90% (MIC90) of the isolates.
Values shown are in µg/mL.
Comparing with the previous period, PNSP decreased significantly from 23.2% in
2012–2015 to 13.9% in 2015–2018 (p = 0.036) and erythromycin resistance showed a non-
significant decrease from 22.7% in 2012–2015 to 17.2% in 2015–2018 (p = 0.220). Among
the PCV13 serotypes, only the PCV7 serotypes 6B, 14, 19F and 23F were associated with
antimicrobial non-susceptibility, while among NVT serotypes, serotypes 15A and 33F
were the major contributors to antimicrobial resistance (Figures 1 and 2). Among PNSP,
serotype 14 was the most frequent (15.4%), while 3 serotypes accounted for more than half
of erythromycin-resistant isolates: 33F (23.1%), 19F (19.2%) and 14 (15.4%).
4. Discussion
Although the number of cases identified by molecular methods remained almost stable
from 2008–2012 and 2012–2015, their proportion of the overall pIPD cases increased [3]. In
2015–2018, the overall number of pIPD cases identified by molecular methods increased
substantially (from n = 47 in 2012–2015 to n = 70) and this was also mirrored in an increase
in the proportion of molecularly identified pIPD cases, from 20.2% to 30.1% (p = 0.007). This
reflects mostly the increasing importance of complicated pneumonia in pIPD in Portugal in
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which pneumococci were frequently identified exclusively by molecular methods in pleural
fluid and suggests that the incidence of pediatric complicated pneumonia in Portugal could
be increasing, similarly to what was reported recently in Australia [21]. Serotype 3 has
been shown to be a major cause of complicated pneumonia worldwide [11,12,21,22] and
it was the most frequently detected serotype in pIPD in Portugal in 2015–2018 (Figure 1),
predominantly detected in pleural fluid samples by molecular methods (n = 43/59, 72.8%).
A persistence of serotype 3 in pIPD is not universally reported, with some countries
finding decreases in infections caused by this serotype following PCV13 vaccination [8–10].
However, the fact that many studies did not include cases detected by molecular methods
could be a major reason behind these differences since it was reported by several groups
that serotype 3 infections are more likely detected when using PCR rather than culture,
particularly in cases of complicated pneumonia with pleural effusion [11,12,21–23].
Similar to the situation described here, other countries failed to detect decreases in
serotype 3 IPD cases. A study in England and Wales found decreases in serotype 3 infections
only in the older age groups (5–64 years and ≥65 years) but not in younger children
(<5 years) up to 2014 [7] and more recent data from England point to an increase in serotype
3 IPD [24]. In France, a rebound in the incidence of serotype 3 IPD in children <2 years to
pre-PCV13 levels was seen in recent years [25]. In Switzerland, after decreases since 2009,
there was a rebound in serotype 3 IPD incidence in children <5 years in 2018–2019 [26]. In
Spain, despite an overall reduction in IPD incidence between 2006 and 2014, the incidence
of serotype 3 disease did not change in children <5 years, in a situation of intermediate
vaccination coverage [27]. Additionally, in the same region of Spain, a study conducted
between 2012 and 2016, allowed the identification of a significant number of vaccine failures
associated with serotype 3, also the most frequent PCV13 serotype causing IPD in the
region [22]. In agreement with what was found in Portugal in the current study, the authors
found more serotype 3 IPD cases in older children (24–59 months) and the proportion
of serotype 3 in age-appropriately vaccinated children was higher than in unvaccinated
patients [22], similarly to the situation previously described in Portugal when analyzing
complicated pneumonia cases between 2010 and 2015 [12]. National data from pIPD in
Spain in 2019, 3-years after the introduction of PCV13 in the NIP, also found serotype 3
among the leading causes of pIPD, together with serotypes 8 and 24F [28]. In Germany,
after the introduction of PCV13, and in a situation of high vaccination coverage, serotype 3
pneumonia with parapneumonic pleural effusion or empyema increased and a considerable
number of vaccine failures were associated with this serotype [11]. All these results seem
to support the lower effectiveness of PCV13 against serotype 3 complicated pneumonia,
although unexplained geographical differences persist [29]. The reasons behind these
differences could be related to different vaccination schedules, risk factors, natural trends,
differences in sampling or transmission dynamics, as already suggested to account for
other differences in serotype replacement [29,30]. Differences in the etiologic diagnosis
methods could potentially further affect the results since the use of molecular methods to
complement culture is essential to avoid underestimating this important serotype in the
epidemiology of pIPD.
The reasons for the lower frequency of serotype 3 infections among children aged
<2 years in our study are unclear, and we can only speculate. One of the possible reasons
could be that older children with serotype 3 IPD were not vaccinated. In Portugal, PCV13
has been in the NIP since July 2015, and some of the older children (>2 years) in our study
could, in fact, be unvaccinated. However, vaccination coverage in Portugal was estimated
to be substantial (62%) even before PCV13 was in the NIP, so differences in the vaccination
status between children <2 years and older children is unlikely to be the sole reason for
the differences in the prevalence of serotype 3 infections in each group. It is possible that
vaccine failures involving serotype 3 occur in vaccinated older children due to the waning
of immunity to this serotype over time. One of the reasons for the lower effectiveness of
PCV13 against serotype 3 was suggested to be the higher IgG levels necessary to protect
against this serotype [31] suggesting that, in contrast to other serotypes, even modest
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antibody waning could lead to a significant lowering of protection. A study conducted in
Massachusetts failed to detect this, with no association between the date of the last vaccine
dose and time to IPD, but the number of serotype 3 infections was low, potentially not
allowing a proper evaluation of the dynamics of this serotype [32].
The geographical differences in the importance of PCV13 serotypes are not exclusive
of serotype 3. In the USA, significant reductions of IPD after 5 years of PCV13 were ac-
companied by major decreases in serotype 19A, but in Europe, this serotype continues to
be a significant cause of disease, despite the use of PCV13 [10,13,24,25,28]. In Portugal,
although a decrease was seen when comparing with the previous study period, serotype
19A still ranked fourth in pIPD. Contrarily to the situation of serotype 14, which is as-
sociated with antimicrobial non-susceptibility potentially contributing to its persistence,
most isolates expressing serotype 19A are now fully susceptible to all antimicrobials tested
(Figure 1), ruling out resistance as the reason for the persistence of this serotype. Serotype
19F infections increased non-significantly when compared with the previous period, which
is worrisome and should be closely monitored, since this serotype was shown to persist,
albeit at low levels, as a cause of IPD in most settings despite being included in PCV7,
which has been used for nearly two decades [33]. Similar to serotype 14, the association of
serotype 19F with antimicrobial non-susceptibility raises the possibility that antimicrobial
use could contribute to its persistence.
The increase in NVTs in pIPD seen here, although reported to be more pronounced
in the adult population [5,33], was also documented in children in many other coun-
tries [7,10,24,25,34]. In agreement with what was reported in this study, in some studies, it
was possible to detect an increase in NVTs in particular age groups, as in children aged
<5 years [7] or <2 years [10]. The increase in serotype 33F when compared with the previous
period could be explained by its association with IPD in younger children and antimicro-
bial resistance, reinforcing the need to closely monitor this emergent serotype. Another
important emergent NVT serotype in pIPD is serotype 8. In Portugal, this serotype was
already identified as an important cause of IPD in adults, with a sustained increase in
this population since 2008 [4,5,35], being the second most important cause of adult IPD
in 2012–2014 [5] and rising to the most frequent in 2015–2018 [35]. Whether the increase
in pIPD will be sustained in the future is still uncertain but its dynamics in the adult
population suggests that it may become an important cause of overall IPD. Serotype 8 was
also identified as an important cause of IPD in other countries where non-PCV13 serotypes
increased as causes of pIPD [10,24,25], reinforcing the need to closely monitor this emergent
serotype previously shown to have an enhanced invasive disease potential [36].
Overall, after PCV13 implementation, serotype replacement was not restricted to a
limited number of serotypes and instead there is now a more diverse group of serotypes
associated with IPD, which also show temporal and geographic differences. In Europe,
the leading causes of NVT disease were found to be serotypes 12F, 10A, 24F, 22F and 15C;
while in North America serotypes 22F, 33F, 15B, 38 and 35B were important [13]. The data
presented here indicate that these geographic differences may be attenuating since several
of the North American serotypes were also important causes of pIPD in Portugal.
The two expanded valency vaccines currently being approved would offer different
potential gains in terms of pIPD prevention, but neither would greatly enhance PCV13
coverage. While PCV15 would cover an additional 7.2% of pIPD cases, PCV20 would more
than double that to cover an additional 16.6% of cases (the potential coverage of PCV20 was
calculated excluding the three samples in which the serotypes could not be unambiguously
identified and that included PCV20 serotypes: 15B/C, 11A/D and 12A/B/F—Figure 2).
Our study has several limitations. The first is our inability to calculate IPD incidence
because we did not receive information regarding cases for which isolates or samples
were not submitted for characterization. However, we believe we are not missing a large
number of cases because in our previous population-based studies, missing samples
represented from 8 to 12% of yearly cases [3]. The stability of our surveillance network, the
active nature of the surveillance and the involvement of both pediatric and microbiology
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departments of many hospitals covering the entire country, further substantiates the
identification of most cases. Therefore, the small decrease in the total number of isolates
and pneumococcal positive samples received in this period (n = 223) relative to the previous
period (n = 232) may be interpreted as evidence of continued stability of the incidence
of pIPD in Portugal. Regarding the serotype distribution of missing samples, we cannot
guarantee that their serotypes would follow the serotype distribution of available samples,
but the expected small proportion of cases with unknown serotype information ensures
that our results would not be strongly affected. Lastly, our study was not designed to
obtain information allowing us to assess the severity of infections caused by the different
serotypes (e.g., hospitalization, ICU admission, 30-day mortality) and we also did not have
comprehensive information on the vaccination status of the cases, which were essential to
identify vaccine failures.
5. Conclusions
In Portugal, after a period of a substantial decline in pIPD, the incidence seems to have
stabilized and PCV13 serotypes remain an important cause of disease, even in a situation of
a mature vaccination program [37] with 3-years of universal PCV13 vaccination. Serotype
3 accounted for over a quarter of all cases, increasing relative to the previous period of
non-universal vaccination. Moreover, the use of molecular methods was instrumental for
the identification of this serotype in pleural fluid, which represented 31% of all samples,
reinforcing the need to use molecular methods to fully understand the dynamics of pIPD.
The increase in NVTs is worrisome, especially serotypes 33F, due to its association with
antimicrobial non-susceptibility, and 8, due to its increasing importance as an emergent
serotype in both pIPD and adult IPD in Portugal. These observations reinforce the need
to continue surveillance studies to better understand the benefits of current vaccination
strategies and to evaluate the potential benefits of future vaccines.
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